FHACT® takes the guess work out of cervical cancer screening

WATCH THE VIDEO >

Get answers,
get FHACT®.
Webinar series.

LEARN MORE >

FHACT® is indicated for HPV-positive ASCUS and LSIL patients.

LEARN MORE >

FHACT® is the only FISH Probe to assess four biomarkers associated with cervical cancer.

Learn More

Latest News

17 Aug 16

Cancer Genetics, Inc. Strengthens Position as a Leader in Myeloid Cancer Diagnosis and Management Receiving New York State Approval for Focus::Myeloid™, a Targeted NGS Panel for Improved Diagnosis, Risk Stratification, and Therapy Selection of Patients with Myeloid Cancers (read more...)

- Focus::Myeloid™ can help clinicians and cancer centers improve the management and treatment of more than 275,000 patients in the U.S. currently (read more...)
09 Aug 16

Cancer Genetics, Inc. Reports Second Quarter 2016 Financial Results and Provides Company Updates (read more...)

- Company Reports Quarterly Revenues of $7 million, an increase of 67% over the Second Quarter of 2015 The Company’s Organic Growth Rate was (read more...)

Events

Clinicians
Patients